Expression of urocortin and its receptors in the rat epididymis by De Luca A. et al.
Original Research Article
Expression of urocortin and its receptors
in the rat epididymis
Adriana De Luca a,*, Giovanna Liguori a, Caterina Squillacioti a,
Salvatore Paino b, Giuseppe Germano a, Sabrina Alì a, Nicola Mirabella a
aDepartment of Veterinary Medicine and Animal Production, University of Naples Federico II, Via Veterinaria 1,
I-80137 Naples, Italy
bDepartment of Sciences of Animal Production, University of Basilicata, Via Nazario Sauro, I-85100 Potenza, Italy
r e p r o d u c t i v e b i o l o g y 1 4 ( 2 0 1 4 ) 1 4 0 – 1 4 7
a r t i c l e i n f o
Article history:
Received 17 January 2013
Accepted 26 January 2014
Available online 5 February 2014
Keywords:
Urocortin
Urocortin receptors
Epididymal cells
Epithelial cells
Fibromuscular cells
a b s t r a c t
Urocortin (UCN; 40 aa) is a corticotrophin-releasing hormone (CRH)-related peptide. The
biological actions of CRH family peptides are mediated by two types of G-protein-coupled
receptors, CRH type 1 receptor (CRHR1) and CRH type 2 receptor (CRHR2). The biological
effects of the peptides are mediated and modulated not only by CRH receptors but also by a
highly conserved CRH-binding protein (CRHBP). The aim of the present study was to
investigate the expression of UCN, CRHR1, CRHR2 and CRHBP by immunohistochemistry,
Western blot, RT-PCR and real-time RT-PCR in the rat epididymis. Urocortin, CRHR1 and
CRHR2, but not CRHBP, were expressed in all segments of the rat epididymis. Speciﬁcally,
UCN- and CRHR2-immunoreactivities (IRs) were distributed in epididymal epithelial cells of
the caput, corpus and cauda. CRHR1-IR was found in the ﬁbromuscular cells surrounding the
epididymal duct and in the smooth musculature of the blood vessels throughout the organ.
UCN and CRHR2 mRNA expression levels were higher in the caput and corpus than in the
cauda, while CRHR1 mRNA level was higher in the cauda than those in the caput and
corpus. In summary, UCN, CRHR1 and CRHR2 are expressed in the rat epididymis. It is
suggested that CRH-related peptides might play multiple roles in the maturation and storage
of spermatozoa.
# 2014 Society for Biology of Reproduction & the Institute of Animal Reproduction and
Food Research of Polish Academy of Sciences in Olsztyn. Published by Elsevier Urban &
Partner Sp. z o.o. All rights reserved.
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Urocortin (UCN) is a peptide (40 amino acids, aa) belonging to
the corticotrophin-releasing hormone (CRH) family and it
exhibits 45% homology to CRH [1–3]. Urocortin was identiﬁed* Corresponding author. Tel.: +39 0812536114; fax: +39 0812536097.
E-mail address: adrideluca@unina.it (A. De Luca).
1642-431X/$ – see front matter # 2014 Society for Biology of Reproduc
Polish Academy of Sciences in Olsztyn. Published by Elsevier Urban &
http://dx.doi.org/10.1016/j.repbio.2014.01.007by Vaughan et al. [4], and similar to CRH, was found to
stimulate adrenocorticotrophic hormone (ACTH) in vitro and
in vivo production by corticotrophs [5]. Additional mammalian
CRH-like peptides include UCN2 (stresscopin-related peptide,
38 aa) and UCN3 (stresscopin) which share more than 80%
of homology [6]. The biological effects of CRH and UCNstion & the Institute of Animal Reproduction and Food Research of
 Partner Sp. z o.o. All rights reserved.
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receptor type 1 (CRHR1) and 2 (CRHR2) [7,8]. CRHR1, primarily
expressed in the central nervous system (CNS) and the anterior
pituitary, is an important mediator of the activation of the
hypothalamic–pituitary–axis (HPA) [9]. CRHR2 is expressed
in extra-CNS sites and has 70% sequence identity to CRHR1.
CRHR2 exhibits high afﬁnity toward UCNs and no toward CRH.
Its activation suppresses multiple metabolic functions includ-
ing feeding in fasted mice [10], feeding-induced edema and
gastric emptying [11]. The biological effects of UCN and other
CRH-related peptides are also modulated by CRH-binding
protein (CRHBP). CRHBP is a 37 kD glycoprotein identiﬁed in
mammals and non-mammalian vertebrates and is highly
conserved during phylogenesis [12]. It was isolated from
human plasma [13,14], the rat brain and the anterior pituitary
[15,16]. CRHBP binds human CRH (hCRH) and UCN with an
equal or greater afﬁnity than CRH receptors [4,17] and
modulates the access of CRH to CRHRs [12]. UCN and CRHRs
gene expression and/or immunoexpression have been
detected in several peripheral organs belonging to the
digestive, cardiovascular, immune, endocrine and reproductive
systems [18–22].
In the male reproductive system, the presence of UCN was
reported in the human prostate, suggesting its role in the
autocrine/paracrine regulation of prostatic function [23].
Moreover, expression of UCN and CRH receptors was found
in the rat, mouse and human testis [22,24,25] and they are
believed to play a role in the regulation of spermatogenesis,
sperm motility and testosterone releasing. To highlight other
sites of urocortin action and to indicate other possible
urocortin functions, we investigated the expression of UCN,
CRHR1, CRHR2 and CRHBP in the rat epididymis.
2. Materials and methods
2.1. Animals and tissue collection
A total of 20 adult male Sprague-Dawley rats (13 weeks of
age; body weight: 380  20 g; purchased from Harlan Italy)
were used. The rats were housed in temperature- and light-
controlled rooms and were given ad libitum access to food
and water. The animals received humane care, and the study
protocol was in compliance with our institution's ethical
guidelines. All procedures followed Italian laws regarding
animal use in research (art. 7 D. Lgs. 116/92). All surgical
procedures were carried out aseptically under anesthesia
induced with urethane (1.2 g/kg). The animals were terminat-
ed under urethane anesthesia, and the removed epididymides
were divided into the following three segments: caput
(including initial segment), corpus and cauda. In addition,
the brain was collected as a positive control. For Western blot
and real-time RT-PCR, the samples were immediately frozen
on dry ice and stored at 80 8C. For immunohistochemical
studies, the samples were immediately ﬁxed in Bouin's ﬂuid.
2.2. Immunoprecipitation and Western blot
Frozen tissues were homogenized in buffer (50 mM Tris–HCl,
pH 7.00; 150 mM NaCl; 2% Triton; 5 mM EDTA; 10 mg/mLleupeptin; 0.1 U/mL aprotinin; 1 mM PMSF) using an Ultra-
Turrax homogenizer and centrifuged at 16 000  g for 20 min
at 4 8C. The protein concentration in the resulting super-
natants was determined by a Bio-Rad assay (Hercules, CA,
USA). Equal amounts of proteins were immunoprecipitated
overnight at 4 8C with anti-UCN, -CRHR1, -CRHR2 and -CRHBP
antisera (1 mg antibody/200 mg protein) previously bound to
protein A/G agarose beads. A fraction of the supernatant
was used as an immunoprecipitation input control (loading
control). Beads were sedimented by brief centrifugation
and washed extensively with ice-cold homogenization
buffer. Proteins solubilized in boiling sodium dodecyl
sulphate (SDS) sample buffer (2% SDS; 5% L-mercaptoethanol;
66 mM Tris, pH 7.5; 10 mM EDTA) were separated on 18%
and 12% SDS-polyacrylamide gels (Bio-Rad), After electro-
phoresis, the proteins were transferred to nitrocellulose
using a semi-dry apparatus (Bio-Rad). The membrane was
incubated for 1 h at 42 8C in 5% bovine serum albumin (BSA;
Sigma, St. Louis, MO, USA) in TBST (150 mM NaCl; 20 mM
Tris–HCl, pH 7.4; 0.3% Tween-20), washed with TBST and
incubated for 2 h at room temperature (RT) in antisera diluted
1:500 in TBST containing 1% BSA. The following primary
antisera were used: polyclonal goat anti-UCN (sc-1825, Santa
Cruz Biotechnology, CA, USA; diluted 1:1000), anti-CRHR1
(sc-12383, Santa Cruz Biotechnology; diluted 1:1000), anti-
CRHR2 (sc-1826, Santa Cruz Biotechnology; diluted 1:1000)
and polyclonal rabbit anti-CRHBP (SAB1300862, Sigma;
diluted 1:1000). The membrane was washed three times
with TBST, incubated for 1 h with anti-goat or anti-rabbit IgG
conjugated to peroxidase (Vector Laboratories, Burlingame,
CA, USA) diluted 1:2000 in 1% BSA containing TBST and
washed three times with TBST. Proteins were visualized by
an enhanced chemiluminescence kit (Amersham, Buckin-
ghamshire, UK). Marker proteins (Prosieve, Lonza) were used
to estimate the molecular weight of each band. b-Actin acted
as the loading control for the immunoprecipitated proteins.
A fraction of the supernatant (50 mg) was separated by
SDS-PAGE and immunoblotted with an anti-b-actin primary
antibody (Mouse mAb JLA20 cp 01; Calbiochem, San Diego,
CA; diluted 1:5000) followed by a peroxidase-conjugated
rabbit anti-mouse IgG secondary antibody (Vector Laborato-
ries; diluted 1: 2000).
2.3. Immunohistochemistry
Fresh tissue fragments were ﬁxed by immersion in Bouin's
ﬁxative (6–24 h), processed for parafﬁn embedding in a
vacuum and cut at a thickness of 3–6 mm. The avidin–
biotin–peroxidase complex (ABC) method was performed by
using the Vectastain ABC kit (Vector Laboratories) [20]. Primary
antisera were the same as those used in the previous section
and were directed against UCN, CRHR1, CRHR2 and CRHBP.
The ﬁrst three were diluted 1:200 and the fourth 1:500. The
secondary antibodies were biotinylated anti-goat or anti-
rabbit IgG (Vector Laboratories; diluted 1:200). The speciﬁcity of
the primary immunoreactions was tested by replacing each
antibody with a buffer, preabsorbing the antibody with an
excess of the appropriate antigen (100 mg antigen/ml antise-
rum as the ﬁnal dilution) or using a dot-blot assay [20]. No
immunoreaction was detected in control tests. The slides were
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Wetzlar, Germany).
2.4. RNA extraction, cDNA synthesis and real-time
RT-PCR
Samples of the epididymis and brain (positive control) were
homogenized in ice-cold TRI-Reagent (Sigma) using an Ultra-
Turrax homogenizer. After chloroform extraction and isopro-
pyl alcohol precipitation, RNA was dissolved in RNAase-free
DEPC water. Total RNA was measured with an Eppendorf
Biophotometer (Eppendorf AG, Basel, Switzerland). For cDNA
synthesis, 1 mg of total RNA was retro-transcribed with the
High Capacity cDNA Reverse Transcription kit (Applied
Biosystems, Carlsbad, CA, USA) using random hexamers as
primers. For conventional and real-time PCR reactions, speciﬁc
primers were designed from the published mRNA Genbank
gene sequences using Primer ExpressT software (PE Applied
Biosystems) and are presented in Table 1. The PCR cycle
conditions were as follows: 94 8C (30 s), 60 8C (30 s), 72 8C
(1 min) for 35 cycles; 72 8C (5 min). The PCR products of rat
urocortin, CRHR1, CRHR2 and CRHBP were puriﬁed using GFX
PCR DNA and Gel Puriﬁcation Kit (28-9034-70, GE Healthcare,
Little Chalfont, Buckinghamshire, UK) and sequenced. To
assess the expression proﬁles of these genes, quantitative RT-
PCR was used. The real-time PCR reactions contained 1 mL
cDNA (40 ng/well) and 24 mL of SYBR Green Master Mix
(Applied Biosystems) containing speciﬁc primers. The PCR
conditions were 50 8C for 2 min and 94 8C for 10 min, followed
by 40 cycles of 94 8C for 15 s and 60 8C for 1 min. The b-actin
gene was also ampliﬁed in separate tubes under the same
conditions to serve as an active endogenous reference to
normalize quantiﬁcation of the mRNA target. Real-time
detection was performed on an ABIPRISM 7300 Sequence
Detection System (Applied Biosystem), and data from the
SYBR Green I PCR amplicons were assessed with ABI 7300
System SDS Software. The relative quantiﬁcation method
2-DDCt (2DDCt) was used for the normalization of gene
expression as described more fully elsewhere [20]. For
statistical analyses, the data were expressed as mean  SD.
Signiﬁcant differences in the UCN, CRHR1 and CRHR2 mRNATable 1 – Primer sequences used in RT-PCR.
Gene Genbank accession number 
UCN NM_019150 Forward
Reverse
CRHR1 NM_030999 Forward
Reverse
CRHR2 NM_022714 Forward
Reverse
CRHBP NM_139183.2 Forward
Reverse
b-Actin V_01217 Forward
Reverse
UCN: urocortin; CRHR1: corticotrophin-releasing hormone type 1 recepto
corticotrophin-releasing hormone-binding protein.levels between the calibrator sample (caput) vs. corpus and
cauda were determined by one-way ANOVA followed by
Tukey's HDS test for independent samples. The level of
statistical signiﬁcance was set at p < 0.05 for all experiments.
3. Results
The results of the Western blot analysis are shown in Fig. 1.
Protein bands corresponding to UCN (16 kD), CRHR1 and
CRHR2 (both 55 kD) were found within caput, corpus and cauda
of epididymis. There was no CRHBP protein expression in the
epididymis, although the protein was expressed in the brain
(a positive control).
Urocortin-immunoreactivity (IR) (Fig. 2A–C) was detected
in the apical portion of the principal epithelial cells of the
caput (Fig. 2A), corpus (Fig. 2B) and cauda (Fig. 2C). CRHR2-IR
(Fig. 2D–F) had the same distribution as UCN-IR. CRHR1-IR was
found in many ﬁbromuscular cells surrounding the epididy-
mal duct throughout the organ (Fig. 2G–I) and in the smooth
musculature of the blood vessels (inset of Fig. 2G and H). No
CRHBP-IR was found in the rat epididymis (Fig. 2L–N).
Urocortin, CRHR1 and CRHR2 mRNAs were expressed in all
segments of the rat epididymis (Fig. 3A), while the presence
of CRHBP mRNA was not found (data not shown). Real-time
PCR conﬁrmed that UCN, CRHR1 and CRHR2 mRNAs were
expressed in all studied segments of the rat epididymis.
The levels of UCN and CRHR2 mRNA expression were higher in
the caput and corpus than in the cauda (Fig. 3B and C). The
levels of CRHR1 mRNA expression were lower in the caput and
corpus than in the cauda (Fig. 3D).
4. Discussion
In the present study, we demonstrated the presence of UCN,
CRHR1 and CRHR2 in the epididymis of the rat by multiple
techniques. CRHBP was not found in the examined organ. The
protein band of approximately 16 kD detected by Western blot
is consistent with the mammalian UCN precursor, which is a
122-aa protein [2,4]. In addition, 55 kD protein bands arePrimer sequences Product size (bp)
: 50-CCATCGACCTCACCTTCCA-30 110
: 50-CTTGCCCACCGAATCGAATA-30
: 50-GGTGACAGCCGCCTACAATT-30 200
: 50-AAGGTACACCCCAGCCAATG-30
: 50-TGGTGCATACCCTGCCCTAT-30 200
: 50-GTGGAGGCTCGCAGTTTTGT-30
: 50-TGGACTGGACACCTCCAAGAT30 200
: 50-ACTCCGGGATGCTGTTTCTG-30
: 50-GCTACAGCTTCACCACCAC-30 498
: 50-TACTCCTGCTTGCTGATCCAC-30
r; CRHR2: corticotrophin-releasing hormone type 2 receptor; CRHBP:
Fig. 1 – Expression of urocortin (UCN), corticotrophin-
releasing hormone receptor type 1 (CRHR1), corticotrophin-
releasing hormone receptor type 2 (CRHR2) and
corticotrophin-releasing hormone binding protein (CRHBP)
in all segments of the rat epididymis (Western blot). Tissue
extracts were immunoprecipitated and immunoblotted
with anti-UCN, -CRHR1, -CRHR2 and -CRHBP antibodies; rat
brain was used as positive control. b-Actin was the loading
control for the immunoprecipitated proteins. kD:
kilodalton.
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CRHBP was found to be expressed in the brain of several
mammalian species [15,16,26,27], it was not detected in the
epididymis in the current study. Therefore, we suggest that
CRHBP does not play a role in antagonizing the effects of CRH-
related peptides in the epididymis as it does in the brain.
In the present study, both UCN- and CRHR2-IRs were
present in principal epithelial cells throughout the epididymis.
Until now, only CRHR2 mRNA was reported to be present in the
rodent epididymis [9,28]. The presence of UCN, CRHR1 and
CRHR2 mRNAs and IRs were described in the mouse testis [24].
UCN, CRHR1 and CRHR2 IRs were found to be distributed in the
testicular germ cells, where UCN seemed to inhibit spermato-
zoa motility and acrosome reaction. In the human testis, UCN
and CRHRs mRNAs and IRs were found to be separately located
among germ, peritubular myoid and Leydig cells, and UCN was
suggested to have receptor-independent effects on germ cell
differentiation and division [25]. In the rat testis, the presence
of UCN mRNA and IR appears to be restricted to Leydig cells
[22,29].The results of the present study raise a question about the
possible roles of UCN in the epididymis. The presence of the
cognate receptor CRHR2 suggests that UCN affects functions of
the epididymal epithelial cells via an autocrine mechanism.
UCN may be involved in the growth modulation of epididymal
epithelial cells. In fact, in the human endometrium, CRH
affected cell growth via CRHR1-mediated activation of the
cAMP–PKA pathway [30]. In non-reproductive epithelial cells,
CRH-related peptides were reported to inﬂuence sebocyte
proliferation [31] and to inhibit apoptosis in gastric cells [32].
Moreover, UCN was found in normal human as well as
adenocarcinomatous human prostates [23], whereas CRHR2
was found in normal prostates but not in prostate cancer
[25,33]. A role for UCN in modulating epididymal hormonal
secretion has also been postulated. CRH and UCN stimulate
pituitary proopiomelanocortin (POMC) gene expression
[4,5,34]. It is well known that the rodent epididymis expresses
POMC [35,36]. Thus, the presence of UCN in the rat epididymis
shown in the present study suggests a possible effect of the
peptide on epididymal POMC-derived hormone secretion, as it
was reported in the placenta [37] and the pituitary gland
[4,5,34].
CRH-related peptides have been demonstrated to modulate
uterine contractility during pregnancy [38,39]. The presence of
CRHR1-IR in the ﬁbromuscular stromal cells surrounding the
epididymal duct suggests a role for CRH-related peptides in the
regulation of the contractility of the epididymis. Moreover,
evidence indicates that, although the epididymis displays rich
innervation, other local, non-neuronal factors participate in
nerve-independent epididymal contractility [40,41]. CRHR1-IR
was also observed in the vascular smooth musculature, thus
suggesting an involvement of CRH-related peptides in the
modulation of the rat epididymal blood ﬂow. This hypothesis
is supported by the ﬁnding that UCN is a dilator of rat [42] and
mouse [43] arteries.
RT-PCR analysis revealed that UCN, CRHR1 and CRHR2, but
not CRHBP, mRNAs were expressed in the rat epididymis, thus
conﬁrming immunohistochemical data. The levels of UCN and
CRHR2 mRNA expression were higher in the caput and corpus
than in the cauda. These results suggest that UCN and CRHR2
may play an important role in the epithelial cell-mediated
maturation of spermatozoa that initially occurs in the caput
and corpus [44]. UCN may inﬂuence the maturation of
spermatozoa via different indirect mechanisms such as
regulating the growth of epididymal epithelial cells and their
hormonal secretion. The levels of CRHR1 mRNA expression
were lower in the caput and corpus than in the cauda, and we
detected CRHR1-IR only in muscle cells. CRH-related peptides
have been demonstrated to modulate uterine contraction
through different signaling pathways. CRHR1 maintains
myometrial quiescence, whereas CRHR2 promotes smooth
muscle contractility [38,39]. The cauda of the epididymis is the
major site of spermatozoa storage in the male reproductive
tract. CRH-related peptides most likely enhance the passage of
spermatozoa through the epididymal duct by inhibiting the
contraction of its ﬁbromuscular cells and facilitating enlarge-
ment of the cauda, which is the site of germ cell storage.
In conclusion, these results clearly demonstrate that UCN,
CRHR1 and CRHR2 are expressed in the rat epididymis and
suggest an existence of a local regulatory system based on
Fig. 2 – Inmmunolocalization of urocortin (UCN) (A–C), corticotrophin-releasing hormone receptor type 2 (CRHR2) (D–F),
corticotrophin-releasing hormone receptor type 1 (CRHR1) (G-I) and corticotrophin-releasing hormone binding protein
(CRHBP) (L–N) in the rat epididymis. UCN-immunoreactivity (IR) and CRHR2-IR were found in the apical area of principal cells
(arrows) of the caput (A,D), corpus (B,E) and cauda (C,F). The principal cells of the epididymal duct were devoid of CRHR1-IR,
but were present in fibromuscular cells of the three epididymal segments (double arrows). The smooth musculature of a few
blood vessels present in the interstitial connective tissue of the caput (G, inset) and corpus (H) shows CRHR1-positive staining
(arrowhead). No CRHBP-IR was found in the epididymal duct (L–N). Negative controls of the caput (O), corpus (P) and cauda
(Q). Bar = 20 mm.
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Fig. 3 – Urocortin (UCN), corticotrophin-releasing hormone receptor type 1 (CRHR1) and corticotrophin-releasing hormone
receptor type 2 (CRHR2) mRNA expression in the rat epididymis detected by RT-PCR (A) and real-time RT-PCR (B–D). (A) UCN
(110-bp) CRHR1 (200-bp) and CRHR2 (200-bp) mRNAs were expressed in the caput, corpus and cauda of the rat epididymis.
Marker: molecular markers of 100-bp ladder. (B–D) The statistical differences in UCN, CRHR1 and CRHR2 mRNA levels
between the calibrator sample (caput) and the corpus and cauda were determined by one-way ANOVA followed by Tukey's
HDS test. Different letters depict significant differences between the examined groups ( p < 0.05).
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urocortinergic system could modulate epididymal physiology
and spermatozoa maturation, storage and deposition.
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